Addex Therapeutics Ltd (ADXN)
8.15
-0.35 (-4.12%)
At close: Mar 03, 2025, 3:12 PM
8.25
1.23%
After-hours: Mar 03, 2025, 02:54 PM EST
No 1D chart data available
| Bid | 7.39 |
| Market Cap | 55.65K |
| Revenue (ttm) | 40.83 |
| Net Income (ttm) | 375.41 |
| EPS (ttm) | -21.47 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | -152.2 |
| Analyst | Buy |
| Ask | 8.5 |
| Volume | 12,825 |
| Avg. Volume (20D) | 20,922 |
| Open | 8.59 |
| Previous Close | 8.50 |
| Day's Range | 7.95 - 8.92 |
| 52-Week Range | 6.67 - 27.90 |
| Beta | 1.94 |
About ADXN
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX7...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2020
Employees 23
Stock Exchange NASDAQ
Ticker Symbol ADXN
Analyst Forecast
According to 1 analyst ratings, the average rating for ADXN stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 268.10% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
-18.65%
Addex Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
5 months ago
+7.96%
Addex Therapeutics shares are trading higher after the company reported H2 financial results.
